Consensus CSL Limited OTC Markets

Stocks

CSLLY

US12637N2045

Pharmaceuticals

Market Closed - OTC Markets 23:51:14 04/06/2026 +04			5-day change	1st Jan Change
16.64 ^USD	+1.96%		-30.98%	-42.22%

08-21	Australian shares close lower as healthcare rally halts; Goodman Group weighs	RE
08-19	Banks drag Australian shares lower; WiseTech slides nearly 9%	RE

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

1d629e908d.qf2KkyKJJj3nf4j_lFCg4A4zHF8rvk35t6_2inw74rg.25v-0kjLanerK9ee1x-QkUl2djpg1yzPhJak0xdjiOeQqLjdS_9cCq4KzQ~65058a782941742fba09ce1d8a83d59d

Analysts' recommendations: CSL Limited

08-18	CSL's Fiscal 2026 Results In Line, Jefferies Says	MT
06-25	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
05-12	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
03-20	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
03-02	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
02-11	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
12-09	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11-11	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
11-07	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
11-07	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
29/10/25	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
29/10/25	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
28/10/25	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
28/10/25	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
02/10/25	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
31/07/25	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
11/07/25	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
10/07/25	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
25/10/24	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
09/09/24	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
05/09/24	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
14/08/24	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
06/03/24	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT
14/02/24	Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight	MT
13/02/24	Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+0.77%
	MODERNA, INC.					-37.03%
	CSL LIMITED					-3.1%
	SAMSUNG BIOLOGICS CO.,LTD.					+26.9%
	UCB					+28.67%
	BIOGEN INC.					+8.67%
	INCYTE CORPORATION					-0.54%
	INNOVENT BIOLOGICS, INC.					+16.58%
	SWEDISH ORPHAN BIOVITRUM AB					+8.17%
	Average					+5.46%
	Weighted average by Cap.					+3.33%